PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer. Mr. Ippolito has over 25 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc. (Valeant), Medicis Pharmaceutical Corporation (Medicis) and Novartis AG.
"We are very excited to have Vince join our team as Chief Commercial Officer. His extensive experience in launching new products and leading sales and marketing efforts to specialty physicians will be invaluable as we develop a commercial strategy for tavaborole and AN2728"
Mr. Ippolito recently served as Senior Vice President, General Manager, Aesthetics at Valeant following its acquisition of Medicis in December 2012. Mr. Ippolito joined Medicis in 2003 as General Manager of Dermatology products, and in 2006, he became Senior Vice President of North American Sales. In 2008, he became Executive Vice President, Sales and Marketing and served in that role until Medicis was acquired. During his tenure at Medicis, he helped launch more than ten new products, including LOPROX® Shampoo, VANOS®, Restylane®, Perlane®, SOLODYN®, ZIANA® and DYSPORT®. Prior to joining Medicis, Mr. Ippolito was employed by Novartis AG from 1986 to 2002, where he served in a variety of sales and marketing roles, including General Manager, Marketing Group Brand Leader for Dermatology and Bone Products where he led the re-launch of Lamisil®, and Vice President of Respiratory, Dermatology and Pediatric sales where he oversaw the launch of four new products including Elidel®.
"We are very excited to have Vince join our team as Chief Commercial Officer. His extensive experience in launching new products and leading sales and marketing efforts to specialty physicians will be invaluable as we develop a commercial strategy for tavaborole and AN2728," said David Perry, Chief Executive Officer of Anacor Pharmaceuticals.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered eight compounds that are currently in development. Its two lead product candidates are topically administered dermatologic compounds — tavaborole, an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the treatment of atopic dermatitis and psoriasis. In addition to its two lead programs, Anacor has discovered three other wholly-owned clinical product candidates — AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. Anacor has also discovered three other compounds that have been out-licensed for further development — one is licensed to Eli Lilly and Company for the treatment of an animal health indication, the second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative, or DNDi, for human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline, LLC for development in tuberculosis. Anacor also has a pipeline of other internally discovered topical and systemic boron-based compounds in development. For more information, visit http://www.anacor.com.
This release contains forward-looking statements, including statements regarding the potential commercialization of tavaborole and AN2728. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including the timing and potential approval of tavaborole by the FDA; the potential for success of tavaborole and our AN2728 compound; and other matters that are described in Anacor's Annual Report on Form 10-K for the year ended December 31, 2012, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications